Phase 1 N=17 Determinants of Alpha-aminoadipic Acid (2-AAA) and Relationship to Diabetes: Study 3
Diabetes Mellitus, Type 2
Primary: Change in Level of 13C 2-AAA in Plasma — 1.742 uM*Hr
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=24 A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Vonoprazan in Adolescents With Symptomatic Gastroesophageal Reflux Disease
Gastroesophageal Reflux
Primary: Maximum Observed Drug Concentration at Steady State (Cmax-ss) of Vonoprazan — 13.4; 26.7 ng/mL
Phase 1 N=22 A Study Comparing Two Forms of Tafamidis Without Food and the Amount of Tafamidis in the Blood With Food
Healthy
Primary: Pharmacokinetics(PK) Parameter - Area Under the Concentration-time Curve to Infinity (AUCinf) of PF-06291826 — 60670; 67690; 60210 Nanograms * hour per milliliter
Phase 1 N=97 Study to Evaluate Safety and Tolerability of PF-07242813 in Healthy Participants and Participants With Atopic Dermatitis
Atopic Dermatitis
Primary: Part 1: SAD Cohorts: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs) — 0; 0; 0; 2 Participants
Phase 1 N=26 A Study to Estimate the Effect of Multiple Dose Abrocitinib on Caffeine, Efavirenz, and Omeprazole in Healthy Participants
Healthy Participants
Primary: Area Under the Plasma Concentration-Time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) of Omeprazole — 238.5; 688.8 ng*hr/mL
Phase 1 N=21 A Study in Healthy Men to Find the Best Formulation for Once Daily Intake of Nintedanib
Healthy
Primary: Area Under the Concentration-time Curve of 3 Different Formulations of Nintedanib (MR1, MR2 and Ofev®) in Plasma Over the Time Interval From 0 Extrapolated to Infinity…
Phase 1 N=65 Safety, Tolerability and Pharmacokinetics of BI 409306 Tablets in Healthy Asian Male Volunteers
Healthy
Primary: Percentage (%) of Subjects With Drug-related Adverse Events (AEs) — 13.3; 9.1; 36.4; 57.9 Percentage of Participants
Phase 1 N=22 Dopaminergic Modulation of Brain Activation Using Simultaneous PET/Pharmacological MRI
Normal Physiology
Primary: The Standardized Uptake Value Ratio (SUVR) for [11C]Raclopride in Putamen — 4.49; 4.39; 4.87 SUV Ratio (SUVR)
Phase 1 N=62 Study to Evaluate the Pharmacokinetics (PK), Safety, and Efficacy of B/F/TAF in Human Immunodeficiency Virus (HIV)-1 Infected, Virologically Suppressed, Pregnant Women in Their Second and Third Trimesters
HIV-1-infection
Primary: Pharmacokinetic (PK) Parameter: AUCtau of Bictegravir (BIC) — 62772.2; 60163.4; 134820.3; 148251.6 hours*nanograms per milliliter (h*ng/mL)
Phase 1 N=36 A Drug Drug Interaction (DDI) Study of Selpercatinib and Dabigatran in Healthy Participants
Healthy
Primary: Pharmacokinetics (PK): Maximum Concentration (Cmax) of Dabigatran — 192; 276 nanogram per milliliter (ng/mL)
Phase 1 N=12 A Study to Compare Two Tablet Forms of Tafamidis in Healthy Participants
Healthy
Primary: Area Under the Plasma Concentration-time Profile From Time Zero Extrapolated to Infinite Time (AUCinf) of Tafamidis (Both Variant 12.2 mg Tafamidis Free Acid Tablet and…
Phase 1 N=7 A Study of Nasal Glucagon (LY900018) in Pediatric Participants With Type 1 Diabetes
Type 1 Diabetes
Primary: Number of Participants With One or More Treatment-Emergent Adverse Event(s) (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to…
Phase 1 N=16 Evaluate the Safety, Tolerability and PK of HF1K16 in Healthy Volunteers
Healthy
Primary: Number of Participants With Adverse Event (AE) and Severe Adverse Event (SAE) — 0; 0; 4; 0 participants
Phase 1 N=114 A Study of Tirzepatide in Overweight and Very Overweight Participants
Obesity · Overweight
Primary: Change From Baseline in Calorie Intake in Participants Receiving Tirzepatide or Placebo at Week 3 — 10.95; -523.15 kilocalories (kcal) — p=<.0001
Phase 1 N=55 Clinical Study to Investigate the Effect of the Combination of Psychotropic Drugs and an Opioid on Ventilation
Hypercapnia · Ventilatory Depression
Primary: Part 1 - Minute Ventilation at the 55 mm Hg End Tidal Carbon Dioxide (CO2) Point (VE55) on Day 1 for Oxycodone Combined With Midazolam and Oxycodone Alone. — 21.9; 24.1…